Christopher Melani, MD, discusses the unmet needs remaining in the mantle cell lymphoma space.
Christopher Melani, MD, assistant research physician, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, discusses the unmet needs remaining in the mantle cell lymphoma (MCL) space.
Findings from phase 1 portion of the ViPOR study (NCT03223610) were presented during the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. ViPOR is a novel combination targeted therapy regimen consisting of venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, and lenalidomide (Revlimid).
While findings of the phase 1b/2 ViPOR study appeared safe for use in patients with MCL and has demonstrated preliminary activity, most therapies have not been able to cure patients with MCL, leaving the field with a major unmet need.
Transcription:
0:08 | MCL is still in general not curable with most therapies. We know that with high-dose chemotherapy we can get 3 or 4 years of remission. When you incorporate induction chemotherapy with autologous stem cell transplant, we're still able to get maybe out to 5 years or 6 years of remission. But again, there's still a continuous rate of relapse even after these intensive therapies.
0:40 | We know that patients who relapse and then go on BTK inhibitor and progress, the median progression-free survival is about 2.5 years, but I think 1 of the current unmet needs is these BTK patients who progress on BTK because again, retrospective studies have shown the median survival is very poor in patients who progress after BTK so what the most appropriate therapy is for those patients. In the ViPOR study, 44% of our patients were BTK had relapsed or refractory to BTK inhibitors. The fact that we're seeing CR rates, even in these patients who were exposed to prior BTK is pretty exciting.
1:32 | I think the BTK failures are certainly some areas in which we have to work on novel therapies. P53-mutated or deleted, patients often have very poor prognosis with standard chemotherapy, and then the blastoid mantle cell patients as well tend to have very aggressive disease and patients don't often respond well to chemotherapy. Whether some of this resistance of blastoid and p53-mutated mantle cells can be overcome from some of these newer novel combination therapy regimens, is still to be determined. We are assessing, we are sequencing our tumors and looking for those mutations to see if I may have overcome some of these negative prognostic markers.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More